{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:03Z","timestamp":1791357483804,"version":"4.3.1"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T00:00:00Z","timestamp":1467417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40263-016-0352-5","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T07:20:41Z","timestamp":1467444041000},"page":"845-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management"],"prefix":"10.1007","volume":"30","author":[{"given":"Fang","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,2]]},"reference":[{"key":"352_CR1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4088\/JCP.v69n0217","volume":"69","author":"K Gao","year":"2008","unstructured":"Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69:302\u20139.","journal-title":"J Clin Psychiatry"},{"key":"352_CR2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4088\/JCP.09r05535gre","volume":"72","author":"K Gao","year":"2011","unstructured":"Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72:1063\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"352_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12264-014-1534-0","volume":"31","author":"K Gao","year":"2015","unstructured":"Gao K, Yuan C, Wu R, Chen J, Wang Z, Fang Y, et al. Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. Neurosci Bull. 2015;31(5):572\u201388.","journal-title":"Neurosci Bull"},{"issue":"1","key":"352_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S146114571000101X","volume":"14","author":"Z Wang","year":"2011","unstructured":"Wang Z, Kemp DE, Chan PK, Fang Y, Ganocy SJ, Calabrese JR, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol. 2011;14(1):131\u201342.","journal-title":"Int J Neuropsychopharmacol"},{"key":"352_CR5","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (CDER). Review guidance: conducting a clinical safety review of a new product application and preparing a report on the review. Good Review Practices, 2005. Rockville: Food and Drug Administration; 2005."},{"key":"352_CR6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.0902-4441.2000.ap90086.x","volume":"101","author":"SJ Cooper","year":"2000","unstructured":"Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand. 2000;101:218\u201325.","journal-title":"Acta Psychiatr Scand"},{"key":"352_CR7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF02245618","volume":"124","author":"DP Kammen van","year":"1996","unstructured":"van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol (Berl). 1996;124:168\u201375.","journal-title":"Psychopharmacol (Berl)"},{"key":"352_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s002130000452","volume":"150","author":"SJ Cooper","year":"2000","unstructured":"Cooper SJ, Butler A, Tweed J, Welch C, Raniwalla J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacol (Berl). 2000;150:237\u201343.","journal-title":"Psychopharmacol (Berl)"},{"key":"352_CR9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","volume":"23","author":"E Garcia","year":"2009","unstructured":"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 2009;23:615\u201325.","journal-title":"CNS Drugs"},{"key":"352_CR10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","volume":"154","author":"DL Zimbroff","year":"1997","unstructured":"Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia, Sertindole Study Group. Am J Psychiatry. 1997;154:782\u201391.","journal-title":"Am J Psychiatry"},{"key":"352_CR11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hup.1254","volume":"27","author":"L Citrome","year":"2012","unstructured":"Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo and active-controlled trials. Hum Psychopharmacol Clin Exp. 2012;27:24\u201332.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"2\u20133","key":"352_CR12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","volume":"152","author":"S Durgam","year":"2014","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2\u20133):450\u20137.","journal-title":"Schizophr Res"},{"key":"352_CR13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763\u201371.","journal-title":"J Clin Psychiatry"},{"key":"352_CR14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681\u201390.","journal-title":"Arch Gen Psychiatry"},{"key":"352_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","volume":"41","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20\u00a0mg\/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007;41:895\u2013905.","journal-title":"J Psychiatr Res"},{"key":"352_CR16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","volume":"68","author":"SG Potkin","year":"2007","unstructured":"Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68:1492\u2013500.","journal-title":"J Clin Psychiatry"},{"key":"352_CR17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","volume":"30","author":"JM Kane","year":"2010","unstructured":"Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30:106\u201315.","journal-title":"J Clin Psychopharmacol"},{"key":"352_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","volume":"164","author":"JM Kane","year":"2015","unstructured":"Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164:127\u201335.","journal-title":"Schizophr Res"},{"issue":"9","key":"352_CR19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","volume":"172","author":"CU Correll","year":"2015","unstructured":"Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870\u201380.","journal-title":"Am J Psychiatry"},{"key":"352_CR20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","volume":"14","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111\u201323.","journal-title":"Neuropsychopharmacology"},{"key":"352_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","volume":"42","author":"LA Arvanitis","year":"1997","unstructured":"Arvanitis LA, Miller BG. Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233\u201346.","journal-title":"Biol Psychiatry"},{"key":"352_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","volume":"53","author":"JH Shen","year":"2014","unstructured":"Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014;53:14\u201322.","journal-title":"J Psychiatr Res"},{"key":"352_CR23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829\u201336.","journal-title":"J Clin Psychiatry"},{"key":"352_CR24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957\u201367.","journal-title":"Am J Psychiatry"},{"key":"352_CR25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670\u20137.","journal-title":"J Psychiatr Res"},{"key":"352_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101\u20139.","journal-title":"Schizophr Res"},{"key":"352_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"M Ogasa","year":"2013","unstructured":"Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacol (Berl). 2013;225:519\u201330.","journal-title":"Psychopharmacol (Berl)"},{"key":"352_CR28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","volume":"124","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine HGAP Study Group. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996;124:159\u201367.","journal-title":"Psychopharmacology"},{"key":"352_CR29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93:117\u201330.","journal-title":"Schizophr Res"},{"key":"352_CR30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90:147\u201361.","journal-title":"Schizophr Res"},{"key":"352_CR31","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62:1363\u201370.","journal-title":"Biol Psychiatry"},{"key":"352_CR32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","volume":"166","author":"CM Canuso","year":"2009","unstructured":"Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166:691\u2013701.","journal-title":"Am J Psychiatry"},{"key":"352_CR33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","volume":"54","author":"JG Small","year":"1997","unstructured":"Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997;54:549\u201357.","journal-title":"Arch Gen Psychiatry"},{"key":"352_CR34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.schres.2006.03.027","volume":"85","author":"SG Potkin","year":"2006","unstructured":"Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006;85:254\u201365.","journal-title":"Schizophr Res"},{"key":"352_CR35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4088\/JCP.v68n0603","volume":"68","author":"RS Kahn","year":"2007","unstructured":"Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:832\u201342.","journal-title":"J Clin Psychiatry"},{"key":"352_CR36","first-page":"11","volume":"41","author":"JP Lindenmayer","year":"2008","unstructured":"Lindenmayer JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull. 2008;41:11\u201335.","journal-title":"Psychopharmacol Bull"},{"key":"352_CR37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","volume":"140","author":"P Keck Jr","year":"1998","unstructured":"Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120\u00a0mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacol (Berl). 1998;140:173\u201384.","journal-title":"Psychopharmacol (Berl)"},{"issue":"8","key":"352_CR38","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"2","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;2(8):S20\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"352_CR39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","volume":"20","author":"DG Daniel","year":"1999","unstructured":"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20:491\u2013505.","journal-title":"Neuropsychopharmacology"},{"key":"352_CR40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","volume":"64","author":"TA Pigott","year":"2003","unstructured":"Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048\u201356.","journal-title":"J Clin Psychiatry"},{"key":"352_CR41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","volume":"72","author":"JM Kane","year":"2011","unstructured":"Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72:349\u201355.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"352_CR42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","volume":"155","author":"G Bondolfi","year":"1998","unstructured":"Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998;155(4):499\u2013504.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"352_CR43","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","volume":"158","author":"JM Azorin","year":"2001","unstructured":"Azorin JM, Spiegel R, Remington G, Vanelle JM, P\u00e9r\u00e9 JJ, Giguere M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158(8):1305\u201313.","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"352_CR44","first-page":"254","volume":"85","author":"KX Zhong","year":"2006","unstructured":"Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006;85(1\u20133):254\u201365.","journal-title":"Schizophr Res"},{"issue":"12","key":"352_CR45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"352_CR46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"352_CR47","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","volume":"160","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651\u20138.","journal-title":"Am J Psychiatry"},{"key":"352_CR48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881106059693","volume":"20","author":"G Sachs","year":"2006","unstructured":"Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536\u201346.","journal-title":"J Psychopharmacol"},{"key":"352_CR49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11:673\u201386.","journal-title":"Bipolar Disord"},{"key":"352_CR50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","volume":"122","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122:27\u201338.","journal-title":"J Affect Disord"},{"key":"352_CR51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","volume":"174","author":"GS Sachs","year":"2015","unstructured":"Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296\u2013302.","journal-title":"J Affect Disord"},{"key":"352_CR52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","volume":"15","author":"AB Smulevich","year":"2005","unstructured":"Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75\u201384.","journal-title":"Eur Neuropsychopharmacol"},{"key":"352_CR53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jad.2011.10.045","volume":"136","author":"H Katagiri","year":"2012","unstructured":"Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord. 2012;136:476\u201384.","journal-title":"J Affect Disord"},{"key":"352_CR54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0269881108099418","volume":"24","author":"E Vieta","year":"2010","unstructured":"Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010;24:547\u201358.","journal-title":"J Psychopharmacol"},{"key":"352_CR55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.euroneuro.2005.02.006","volume":"15","author":"RS McIntyre","year":"2005","unstructured":"McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573\u201385.","journal-title":"Eur Neuropsychopharmacol"},{"key":"352_CR56","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","volume":"156","author":"M Tohen","year":"1999","unstructured":"Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156:702\u20139.","journal-title":"Am J Psychiatry"},{"key":"352_CR57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","volume":"57","author":"M Tohen","year":"2000","unstructured":"Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000;57:841\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"352_CR58","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4088\/JCP.v69n1113","volume":"69","author":"M Tohen","year":"2008","unstructured":"Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69:1776\u201389.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"352_CR59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-5618.2010.00815.x","volume":"12","author":"E Vieta","year":"2010","unstructured":"Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230\u201343.","journal-title":"Bipolar Disord"},{"key":"352_CR60","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1185\/030079905X46340","volume":"21","author":"E Vieta","year":"2005","unstructured":"Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21:923\u201334.","journal-title":"Curr Med Res Opin"},{"key":"352_CR61","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.clinthera.2011.10.002","volume":"33","author":"AJ Cutler","year":"2011","unstructured":"Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther. 2011;33:1643\u201358.","journal-title":"Clin Ther"},{"key":"352_CR62","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","volume":"161","author":"RM Hirschfeld","year":"2004","unstructured":"Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057\u201365.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"352_CR63","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","volume":"160","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741\u20138.","journal-title":"Am J Psychiatry"},{"key":"352_CR64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","volume":"25","author":"SG Potkin","year":"2005","unstructured":"Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301\u201310.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"352_CR65","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0269881108099418","volume":"24","author":"E Vieta","year":"2010","unstructured":"Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010;24(4):547\u201358.","journal-title":"J Psychopharmacol"},{"key":"352_CR66","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4088\/JCP.v67n0414","volume":"67","author":"PE Keck Jr","year":"2006","unstructured":"Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626\u201337.","journal-title":"J Clin Psychiatry"},{"key":"352_CR67","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.euroneuro.2012.03.004","volume":"22","author":"E Vieta","year":"2012","unstructured":"Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22:825\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"352_CR68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","volume":"163","author":"M Tohen","year":"2006","unstructured":"Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247\u201356.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"352_CR69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2012.01.047","volume":"138","author":"J Berwaerts","year":"2012","unstructured":"Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord. 2012;138(3):247\u201358.","journal-title":"J Affect Disord"},{"key":"352_CR70","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4088\/JCP.11m06878","volume":"72","author":"RH Weisler","year":"2011","unstructured":"Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011;72:1452\u201364.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"352_CR71","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218\u201326.","journal-title":"Arch Gen Psychiatry"},{"key":"352_CR72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","volume":"28","author":"ME Thase","year":"2008","unstructured":"Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28:13\u201320.","journal-title":"J Clin Psychopharmacol"},{"key":"352_CR73","doi-asserted-by":"crossref","unstructured":"Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, N\u00e9meth G, Vieta E, Calabrese JR, Yatham LN. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2015:appiajp201515020164 (Epub ahead of print).","DOI":"10.1176\/appi.ajp.2015.15020164"},{"key":"352_CR74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160\u20138.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"352_CR75","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079\u201388.","journal-title":"Arch Gen Psychiatry"},{"key":"352_CR76","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1192\/bjp.bp.112.108357","volume":"201","author":"M Tohen","year":"2012","unstructured":"Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, et al. Randomised, double-blind,\u00a0placebo-controlled study of\u00a0olanzapine\u00a0in patients with bipolar I depression. Br J Psychiatry. 2012;201:376\u201382.","journal-title":"Br J Psychiatry"},{"key":"352_CR77","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351\u201360.","journal-title":"Am J Psychiatry"},{"key":"352_CR78","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"352_CR79","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","volume":"71","author":"SL McElroy","year":"2010","unstructured":"McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163\u201374.","journal-title":"J Clin Psychiatry"},{"key":"352_CR80","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","volume":"71","author":"AH Young","year":"2010","unstructured":"Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71:150\u201362.","journal-title":"J Clin Psychiatry"},{"key":"352_CR81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","volume":"121","author":"T Suppes","year":"2010","unstructured":"Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121:106\u201315.","journal-title":"J Affect Disord"},{"key":"352_CR82","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCP.0b013e3182917f3f","volume":"33","author":"K Gao","year":"2013","unstructured":"Gao K, Pappadopulos E, Karayal ON, Kolluri S, Calabrese JR. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol. 2013;33:425\u201331.","journal-title":"J Clin Psychopharmacol"},{"key":"352_CR83","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/15622975.2012.665177","volume":"15","author":"AH Young","year":"2014","unstructured":"Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014;15:96\u2013112.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"352_CR84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852913000904","volume":"19","author":"AD Loebel","year":"2014","unstructured":"Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014;19(2):197\u2013205.","journal-title":"CNS Spectr"},{"key":"352_CR85","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neubiorev.2007.02.004","volume":"31","author":"S Datta","year":"2007","unstructured":"Datta S, Maclean RR. Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence. Neurosci Biobehav Rev. 2007;31:775\u2013824.","journal-title":"Neurosci Biobehav Rev"},{"key":"352_CR86","doi-asserted-by":"crossref","first-page":"845","DOI":"10.5665\/SLEEP.1112","volume":"34","author":"RA Espa\u00f1a","year":"2011","unstructured":"Espa\u00f1a RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep. 2011;34:845\u201358.","journal-title":"Sleep"},{"key":"352_CR87","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","volume":"31","author":"H Uchida","year":"2011","unstructured":"Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497\u2013502.","journal-title":"J Clin Psychopharmacol"},{"key":"352_CR88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2133\/dmpk.20.187","volume":"20","author":"A Matsui-Sakata","year":"2005","unstructured":"Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet. 2005;20:187\u201399.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"352_CR89","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2125.2008.03143.x","volume":"65","author":"M Tashiro","year":"2008","unstructured":"Tashiro M, Duan X, Kato M, Miyake M, Watanuki S, Ishikawa Y, et al. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol. 2008;65(6):811\u201321.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"352_CR90","first-page":"245","volume":"52","author":"HM Bigott-Hennkens","year":"2008","unstructured":"Bigott-Hennkens HM, Dannoon S, Lewis MR, Jurisson SS. In vitro receptor binding assays: general methods and considerations. Q J Nucl Med Mol Imaging. 2008;52(3):245\u201353.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"8","key":"352_CR91","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s002280050676","volume":"55","author":"Y Sekine","year":"1999","unstructured":"Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol. 1999;55(8):583\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"352_CR92","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"352_CR93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23:65\u201373.","journal-title":"J Psychopharmacol"},{"key":"352_CR94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3 Suppl","key":"352_CR95","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/1939-4551-4-S3-S22","volume":"4","author":"DS Church","year":"2011","unstructured":"Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011;4(3 Suppl):S22\u20137.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"352_CR96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00421306","volume":"41","author":"T Sagal\u00e9s","year":"1975","unstructured":"Sagal\u00e9s T, Erill S. Effects of central dopaminergic blockade with primozide upon the EEG stages of sleep in man. Psychopharmacologia. 1975;41(1):53\u20136.","journal-title":"Psychopharmacologia"},{"key":"352_CR97","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2010.11.003","volume":"15","author":"JM Monti","year":"2011","unstructured":"Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15:269\u201381.","journal-title":"Sleep Med Rev"},{"key":"352_CR98","doi-asserted-by":"crossref","unstructured":"van Laar M, Volkerts E, VerbatenM. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A\/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 2001;154:189\u201397.","DOI":"10.1007\/s002130000633"},{"key":"352_CR99","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.smrv.2011.12.003","volume":"16","author":"CW Berridge","year":"2012","unstructured":"Berridge CW, Schmeichel BE, Espa\u00f1a RA. Noradrenergic modulation of wakefulness\/arousal. Sleep Med Rev. 2012;16:187\u201397.","journal-title":"Sleep Med Rev"},{"key":"352_CR100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0306-4522(00)00215-3","volume":"99","author":"CW Berridge","year":"2000","unstructured":"Berridge CW, Espa\u00f1a RA. Synergistic sedative effects of noradrenergic alpha(1)- and beta-receptor blockade on forebrain electroencephalographic and behavioral indices. Neuroscience. 2000;99:495\u2013505.","journal-title":"Neuroscience"},{"key":"352_CR101","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-3-642-23274-9_11","volume":"208","author":"JS Yeomans","year":"2012","unstructured":"Yeomans JS. Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions. Handb Exp Pharmacol. 2012;208:243\u201359.","journal-title":"Handb Exp Pharmacol"},{"key":"352_CR102","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/WNR.0b013e328349739b","volume":"22","author":"Y Wu","year":"2011","unstructured":"Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, et al. Evidence that clozapine directly interacts on the GABAB receptor. Neuroreport. 2011;22:637\u201341.","journal-title":"Neuroreport"},{"key":"352_CR103","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1476-5381.2009.00175.x","volume":"157","author":"S Yamamura","year":"2009","unstructured":"Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T, et al. Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br J Pharmacol. 2009;157:656\u201365.","journal-title":"Br J Pharmacol"},{"key":"352_CR104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.peptides.2010.10.023","volume":"32","author":"K Mori","year":"2011","unstructured":"Mori K, Kim J, Sasaki K. Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. Peptides. 2011;32:246\u201352.","journal-title":"Peptides"},{"issue":"6","key":"352_CR105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2125.2011.03902.x","volume":"71","author":"M Liem-Moolenaar","year":"2011","unstructured":"Liem-Moolenaar M, Rad M, Zamuner S, Cohen AF, Lemme F, Franson KL, et al. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol. 2011;71(6):907\u201316.","journal-title":"Br J Clin Pharmacol"},{"issue":"2\u20133","key":"352_CR106","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jad.2012.12.004","volume":"148","author":"K Gao","year":"2013","unstructured":"Gao K, Wang Z, Chen J, Kemp DE, Chan PK, Conroy CM, et al. Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J Affect Disord. 2013;148(2\u20133):256\u201364.","journal-title":"J Affect Disord"},{"key":"352_CR107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1399-5618.2010.00823.x","volume":"12","author":"DE Kemp","year":"2010","unstructured":"Kemp DE, Gao K, Chan P, Ganocy SJ, Findling RL, Calabrese JR. Mecial Comorbidity in bipolar disorder: relationship between illnesses of the endocrine\/metabolic system and treament outcome. Bipolar Disord. 2010;12:404\u201313.","journal-title":"Bipolar Disord."},{"issue":"3","key":"352_CR108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2190\/PM.41.3.c","volume":"41","author":"DA Casey","year":"2011","unstructured":"Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med. 2011;41(3):245\u201351.","journal-title":"Int J Psychiatry Med."},{"key":"352_CR109","first-page":"1145","volume":"9","author":"K Gao","year":"2013","unstructured":"Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1145\u201357.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"352_CR110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2013.07.039","volume":"150","author":"JB Lohr","year":"2013","unstructured":"Lohr JB, Liu L, Caligiuri MP, Kash TP, May TA, Murphy JD, et al. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2013;150:289\u201396.","journal-title":"Schizophr Res"},{"key":"352_CR111","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.09.013","volume":"60","author":"C Andrade","year":"2015","unstructured":"Andrade C, Kisely S, Monteiro I, Rao S. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2015;60:14\u201321.","journal-title":"J Psychiatr Res"},{"key":"352_CR112","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","volume":"147","author":"JP Lindenmayer","year":"2013","unstructured":"Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013;147:241\u201352.","journal-title":"Schizophr Res."},{"key":"352_CR113","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.07r03982","volume":"70","author":"C Saavedra-Velez","year":"2009","unstructured":"Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009;70:104\u201312.","journal-title":"J Clin Psychiatry"},{"key":"352_CR114","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","volume":"70","author":"O Freudenreich","year":"2009","unstructured":"Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009;70:1674\u201380.","journal-title":"J Clin Psychiatry"},{"key":"352_CR115","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/npp.2013.111","volume":"38","author":"RA Lasser","year":"2013","unstructured":"Lasser RA, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci ML, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013;38:2140\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"352_CR116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/med\/9780199300532.003.0022","volume-title":"Bipolar book: history, neurobiology, and treatment","author":"K Gao","year":"2015","unstructured":"Gao K, Wu R, Grunze H, Calabrese JR. Phamarcological treatment of acute bipolar depression. In: Yildiz A, Ruiz P, Nemeroff C, editors. Bipolar book: history, neurobiology, and treatment. New York: Oxford University Press; 2015. p. 281\u201398."},{"issue":"1","key":"352_CR117","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S1461145712000326","volume":"16","author":"B Dell\u2019Osso","year":"2013","unstructured":"Dell\u2019Osso B, Ketter TA. Use of adjunctive stimulants in adult bipolar depression. Int J Neuropsychopharmacol. 2013;16(1):55\u201368.","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0352-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0352-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:12:03Z","timestamp":1692414723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0352-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,2]]},"references-count":117,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0352-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,2]]}}}